Candriam Luxembourg S.C.A. bought a new position in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) in the fourth quarter, Holdings Channel reports. The fund bought 145,000 shares of the company’s stock, valued at approximately $1,995,000.
Other hedge funds have also recently modified their holdings of the company. Northern Trust Corp bought a new position in shares of Eidos Therapeutics during the 2nd quarter worth $281,000. JPMorgan Chase & Co. bought a new position in shares of Eidos Therapeutics during the 3rd quarter worth $167,000. Bank of New York Mellon Corp bought a new position in shares of Eidos Therapeutics during the 3rd quarter worth $137,000. BlackRock Inc. grew its stake in shares of Eidos Therapeutics by 385.1% during the 3rd quarter. BlackRock Inc. now owns 727,698 shares of the company’s stock worth $7,264,000 after acquiring an additional 577,698 shares during the period. Finally, American International Group Inc. bought a new position in shares of Eidos Therapeutics during the 3rd quarter worth $2,393,000. Hedge funds and other institutional investors own 30.15% of the company’s stock.
Several research analysts have recently weighed in on EIDX shares. JPMorgan Chase & Co. upgraded Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 27th. Leerink Swann started coverage on Eidos Therapeutics in a research note on Tuesday, November 27th. They set an “outperform” rating and a $32.00 price target for the company. BMO Capital Markets started coverage on Eidos Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $28.00 price target for the company. Finally, ValuEngine downgraded Eidos Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Eidos Therapeutics presently has a consensus rating of “Buy” and an average target price of $27.00.
In related news, CFO Christine Siu sold 11,913 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
ILLEGAL ACTIVITY NOTICE: “Candriam Luxembourg S.C.A. Buys New Position in Eidos Therapeutics Inc (EIDX)” was first published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2019/03/26/candriam-luxembourg-s-c-a-buys-new-position-in-eidos-therapeutics-inc-eidx.html.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Want to see what other hedge funds are holding EIDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eidos Therapeutics Inc (NASDAQ:EIDX).
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.